The Column Group Discloses 11.6% Stake in Eikon Therapeutics, Invests $38.12M in IPO

summarizeSummary

The Column Group and its managing partners have disclosed a significant 11.6% beneficial ownership in Eikon Therapeutics, including a substantial $38.12 million investment in the company's recent IPO at a price above the current market value.

check_boxKey Events

• Significant Beneficial Ownership Established

  The Column Group entities and their managing partners, Peter Svennilson and Tim Kutzkey, collectively report beneficial ownership of 11.6% of Eikon Therapeutics' common stock.

• Substantial IPO Investment

  The Column Group entities purchased approximately $38.12 million worth of common stock at $18.00 per share in connection with the company's initial public offering on February 6, 2026.

• Long-Term Investor Commitment

  The Column Group has been a long-term investor, converting various series of preferred stock into common stock upon the IPO, and has entered into a 180-day lock-up agreement.

auto_awesomeAnalysis

This Schedule 13D filing reveals that The Column Group, a venture capital firm, and its managing partners, Peter Svennilson and Tim Kutzkey, have established a significant beneficial ownership stake of 11.6% in Eikon Therapeutics following the company's initial public offering. The filing details substantial purchases totaling approximately $38.12 million made by The Column Group entities at the IPO price of $18.00 per share on February 6, 2026. This significant investment, coupled with their long-standing involvement as preferred stockholders and the commitment to a 180-day lock-up period, signals strong conviction in the company's long-term prospects, especially given the IPO price was above the current market price. This filing provides a comprehensive view of a major institutional investor's commitment to Eikon Therapeutics.